A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
Completed · Phase 1 · NCT05696847
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $106,771
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2023-02-07; completion 2025-01-16
- Results posted
- Yes
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.
From ClinicalTrials.gov, last updated 2025-08-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $106,771 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Robert A. Riesenberg, MD Psychiatry · Atlanta, GA
- Carl P. Griffin, M.D. Family Medicine · Oklahoma City, OK
- Stephanie R. Sisley, MD Pediatric Endocrinology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Baylor College of Medicine $73,330
- Lynn Health Science Institute $23,651
- Atlanta Center for Medical Research $9,790
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.